Professor Michael Lind's Outputs (6)

PTEN protein expression in malignant pleural mesothelioma (2012)
Journal Article
Agarwal, V., Campbell, A., Beaumont, K. L., Cawkwell, L., & Lind, M. J. (2013). PTEN protein expression in malignant pleural mesothelioma. Tumor Biology, 34(2), 847-851. https://doi.org/10.1007/s13277-012-0615-9

Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitut... Read More about PTEN protein expression in malignant pleural mesothelioma.

Proteomic identification of putative biomarkers of radiotherapy resistance (2012)
Thesis
Scaife, L. Proteomic identification of putative biomarkers of radiotherapy resistance. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4214086

Background
Currently, tumour response to radiotherapy cannot be predicted meaning that those patients with tumours resistant to the therapy endure the harmful side effects associated with ionising radiation in the absence of therapeutic gain. The ai... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance.

Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer (2012)
Thesis
ElFadl, D. Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4218629

Background:
Breast cancer is an important health issue. The majority of patients present with early stage cancer and are therefore candidates for breast conserving surgery and radiotherapy. A proportion will suffer from local recurrence, which may b... Read More about Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer.

Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer (2012)
Journal Article
Hodgkinson, V. C., Agarwal, V., ElFadl, D., Fox, J. N., McManus, P. L., Mahapatra, T. K., Kneeshaw, P. J., Drew, P. J., Lind, M., & Cawkwell, L. (2012). Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics, 75(9), 2745-2752. https://doi.org/10.1016/j.jprot.2012.03.049

Neoadjuvant chemotherapy is used to treat oestrogen receptor-positive breast cancer however chemo-resistance is a major obstacle in this molecular subtype. The ability to predict tumour response would allow chemotherapy administration to be directed... Read More about Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer.

The significance of the EGFR pathway in malignant pleural mesothelioma (2012)
Thesis
Agarwal, V. (. The significance of the EGFR pathway in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. https://hull-repository.worktribe.com/output/4214047

Introduction
EGFR, MTOR and COX2 are up regulated in malignant pleural mesothelioma (MPM). In this study we aimed to determine the expression of Lipoxygenase enzymes (LOX), absence of PTEN protein expression and the cytotoxic effect of EGFR, MTOR an... Read More about The significance of the EGFR pathway in malignant pleural mesothelioma.

Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? (2012)
Journal Article
Hodgkinson, V. C., ELFadl, D., Agarwal, V., Garimella, V., Russell, C., Long, E. D., Fox, J. N., McManus, P. L., Mahapatra, T. K., Kneeshaw, P. J., Drew, P. J., Lind, M. J., & Cawkwell, L. (2012). Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics, 75(4), 1276-1283. https://doi.org/10.1016/j.jprot.2011.11.005

Introduction: Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for estrogen receptor-positive breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only thos... Read More about Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?.